Journal List > J Gynecol Oncol > v.26(3) > 1079184

TOOLS
Khan, Fatima, and Rameez: Impact of statins on risk and survival of ovarian cancer
Correspondence

Journal of Gynecologic Oncology 2015; 26(3): 240-241.

Published online: 8 July 2015

DOI: https://doi.org/10.3802/jgo.2015.26.3.240

Impact of statins on risk and survival of ovarian cancer

Muhammad Shahzeb Khan, Kaneez Fatima, Rameez

Civil Hospital, Dow University of Health Sciences, Karachi, Pakistan.

Correspondence to Muhammad Shahzeb Khan. Civil Hospital, Dow University of Health Sciences, Baba-E-Urdu Road, Karachi 74200, Pakistan. shahzebkhan@gmail.com

Copyright © 2015. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
To the editor: While statins have been clearly shown to decrease mortality and morbidity in cardiovascular diseases, the role of statins as an anti-cancer agent is less well defined. Predicted through new guidelines published by American College of Cardiology, it is said that around 30% of Americans in the age group 40 to 75 will be using statins even if they do not have cardiovascular disease [1]. Recently, statin's beneficial effect on cancer survival has also been highlighted in many studies. A Danish study [2] reported that people who have used statins have 20% lower chance of cancer deaths compared with those who have not used statins. Similarly studies have also shown that statins lower the incidence of common cancers such as breast, prostate and colorectal. This anticancer activity of statins is due to inhibition of isoprenoid biosynthesis which is essential for cancer growth and metastasis [34].
Ovarian cancer has the worst prognosis among gynecological cancers. It has been estimated that ovarian cancer causes approximately 15,000 deaths in USA annually [5]. Therefore, identification of protective factors and possible agents associated with increased survival can have great implications. Statin's role in ovarian cancer has been controversial with varying opinions. In order to collect all the evidence, we conducted a literature search utilizing Medline (PubMed and Ovid) and Cochrane Library to identify studies related to statins effect on incidence and survival in ovarian cancer. Eight relevant citations were found and are summarized in Table 1. Only three studies [678] were found which reported the effect of statin therapy on ovarian cancer survival while the others [910111213] only reported risk of ovarian cancer.
Habis et al. [6] reported a decrease in hazards of disease-specific death (adjusted hazard ratio, 0.23; p=0.04) among statin users in non-serous papillary epithelial ovarian cancer. Similarly Elmore et al. [7] showed significantly longer survival in statin users (62 months) compared with non-users (46 months, p=0.04). Out of the six studies [8910111213] reporting risk of ovarian cancer, only one found a significant reduction in ovarian cancer incidence with statin usage. Baandrup et al. [9] documented a decrease risk only with respect to mucinous ovarian cancer enforcing the need for further subgroup analysis.
When findings of five studies [810111213] were pooled in a meta-analysis conducted by Liu et al. [14], a significant 21% risk reduction was seen (relative risk [RR], 0.79; 95% confidence interval [CI], 0.64 to 0.98). The RR reduction was found to be 52% when long term statin usage was considered (RR, 0.48; 95% CI, 0.28 to 0.80). In conclusion, we suggest that statins impact on ovarian cancer warrants further investigation with larger randomized controlled trials as observational studies are subject to bias and may lead to false slight benefits. Effect of statins with respect to different histological subtypes also need to be further studied.

Figures and Tables

Table 1

Summary of the evidence regarding impact of statin therapy on risk and survival of ovarian cancer

jgo-26-240-i001
Study Type of study Size of population Primary outcome variable Conclusion
Habis et al. (2014) [6] Retrospective cohort 442 Progression-free survival and disease-specific survival Improved survival among statin users was not seen except in non-serous papillary epithelial ovarian cancer
Elmore et al. (2008) [7] Retrospective cohort 126 Progression-free survival and overall survival Improved survival was seen in statin users
Lavie et al. (2013) [8] Case control study Cases, 12; matched controls, 126 Risk of ovarian cancer and survival Decreased risk along with improved survival was reported
Baandrup et al. (2015) [9] Case control study Cases, 4,103; matched controls, 58,706 Risk of epithelial ovarian cancer Decreased risk seen in mucinous ovarian cancer. No association with epithelial subtype
Yu et al. (2009) [10] Retrospective cohort 73,336 Risk of ovarian cancer Non-significant decrease in ovarian cancer risk was found
Kaye et al. (2004) [11] Case control study Cases, 91; controls, 7,393 Risk of ovarian cancer Statins have no substantial effect on ovarian cancer risk
Friedman et al. (2008) [12] Retrospective cohort 361,859 Risk of ovarian cancer No association was found
Clearfield et al. (2001) [13] Randomized controlled trial 997 Risk of ovarian cancer No difference in frequency of cancer between statin users/non-users was reported

Notes

CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported.

References

1. Lloyd-Jones DM, Goff D, Stone NJ. Statins, risk assessment, and the new American prevention guidelines. Lancet. 2014; 383:600–602.
2. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012; 367:1792–1802.
3. Taylor ML, Wells BJ, Smolak MJ. Statins and cancer: a meta-analysis of case-control studies. Eur J Cancer Prev. 2008; 17:259–268.
4. Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012; 64:102–146.
5. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9–29.
6. Habis M, Wroblewski K, Bradaric M, Ismail N, Yamada SD, Litchfield L, et al. Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. PLoS One. 2014; 9:e104521.
7. Elmore RG, Ioffe Y, Scoles DR, Karlan BY, Li AJ. Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol Oncol. 2008; 111:102–105.
8. Lavie O, Pinchev M, Rennert HS, Segev Y, Rennert G. The effect of statins on risk and survival of gynecological malignancies. Gynecol Oncol. 2013; 130:615–619.
9. Baandrup L, Dehlendorff C, Friis S, Olsen JH, Kjaer SK. Statin use and risk for ovarian cancer: a Danish nationwide case-control study. Br J Cancer. 2015; 112:157–161.
10. Yu O, Boudreau DM, Buist DS, Miglioretti DL. Statin use and female reproductive organ cancer risk in a large population-based setting. Cancer Causes Control. 2009; 20:609–616.
11. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004; 90:635–637.
12. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008; 17:27–36.
13. Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W, Shapiro DR, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med. 2001; 10:971–981.
14. Liu Y, Qin A, Li T, Qin X, Li S. Effect of statin on risk of gynecologic cancers: a meta-analysis of observational studies and randomized controlled trials. Gynecol Oncol. 2014; 133:647–655.
TOOLS
Similar articles